OTCMKTS:GNFTF Genfit (GNFTF) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free GNFTF Stock Alerts $5.53 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$5.53▼$5.5350-Day Range$2.95▼$5.5352-Week Range$2.95▼$5.53VolumeN/AAverage Volume625 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Genfit alerts: Email Address Ad Behind the MarketsWill this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.Get the full story here >>> About Genfit Stock (OTCMKTS:GNFTF)Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFTF Stock News HeadlinesApril 16, 2024 | fool.comGenfit (OTC: GNFTF)March 8, 2024 | msn.comInventiva resumes Phase 3 study for NASH drug, stock up 6%December 11, 2023 | markets.businessinsider.comOptimistic Outlook for Genfit: Justine Telliez Raises Target Price Amid Positive Drug DevelopmentsDecember 9, 2023 | markets.businessinsider.comBuy Rating Affirmed for Genfit SA on Strong Elafibranor Efficacy and Favorable Regulatory ProspectsDecember 8, 2023 | markets.businessinsider.comGENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)November 15, 2023 | lse.co.ukGenfit Share Price (GNFT.PA)November 14, 2023 | marketwatch.comIpsen, Genfit Drug Fights Liver Disease Progression, Phase-Three Trial FindsNovember 12, 2023 | seekingalpha.comGenfit reports 9M resultsSeptember 23, 2023 | markets.businessinsider.comKepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)July 4, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Genfit SA (GNFT)June 30, 2023 | marketwatch.comGenfit Shares Jump 27% After Positive Phase 3 Trial ResultsJune 30, 2023 | msn.comU.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver diseaseJune 7, 2023 | markets.businessinsider.comGenfit Gears Up For Primary Biliary Cholangitis Trial DataJune 3, 2023 | markets.businessinsider.comGenfit (GNFTF) Receives a Buy from Kepler CapitalApril 21, 2023 | msn.comODDO BHF Maintains Genfit (EPA:GNFT) Buy RecommendationApril 21, 2023 | msn.comSVB SECURITIES Maintains Genfit (EPA:GNFT) Outperform RecommendationJanuary 24, 2023 | benzinga.comGENFIT Announces 2023 Financial CalendarNovember 23, 2022 | seekingalpha.comA Long Wait For Genfit May Be Worth ItSeptember 29, 2022 | nz.finance.yahoo.comGENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of VersantisSeptember 19, 2022 | finance.yahoo.comGENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver DiseasesSeptember 14, 2022 | thestreet.comGenfit Tortures Fatty Liver Drug to Extract Positive Results From Failed StudySeptember 13, 2022 | finance.yahoo.comFDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 12, 2022 | thestreet.comGenfit's French Fans Fume Following Failure of Fatty Liver DrugSeptember 9, 2022 | finance.yahoo.comGenfit S.A. (GNFT)August 20, 2022 | reuters.comGNFT.OQ - Genfit SA (ADR) | Stock Price & Latest News | ReutersSee More Headlines Receive GNFTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GNFTF CUSIPN/A CIKN/A Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees159Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 69)Co-Founder & Chairman of the Board Comp: $390.36kMr. M. Pascal Prigent (Age 55)Chief Executive Officer Comp: $606.34kProf. Bart Staels (Age 61)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 49)Chief Financial Officer Mr. Pascal Caisey (Age 55)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 50)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 62)Chief Scientific Officer Comp: $772.76kMr. Jean-Christophe Marcoux (Age 46)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 53)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 42)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GNFTF Stock Analysis - Frequently Asked Questions How have GNFTF shares performed in 2024? Genfit's stock was trading at $3.45 at the start of the year. Since then, GNFTF shares have increased by 60.3% and is now trading at $5.53. View the best growth stocks for 2024 here. Are investors shorting Genfit? Genfit saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 56,900 shares, an increase of 111.5% from the April 30th total of 26,900 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. View Genfit's Short Interest. How do I buy shares of Genfit? Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNFTF) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.